Liu David Q, Karanam Bindhu V, Doss George A, Sidler Rick R, Vincent Stella H, Hop Cornelis E C A
Merck Research Labora tories, Department of Drug Metabolism, RY80L-109, P.O. Box 2000, Rahway, NJ 07065, USA.
Drug Metab Dispos. 2004 Sep;32(9):1023-31. doi: 10.1124/dmd.104.000059.
The in vitro metabolism of MK-0767 [(+/-)-5-[(2,4-dioxothiazolidin-5-yl) methyl]-2-methoxy-N-[[(4-trifluoromethyl)-phenyl] methyl]benzamide], a novel 2,4-thiazolidinedione (TZD)-containing peroxisome proliferator-activated receptor alpha/gamma agonist, was studied in rat, dog, monkey, and human liver microsomes and hepatocytes, as well as in recombinant human CYP3A4-containing microsomes. Twenty-two metabolites (some at trace levels) were detected by liquid chromatography-tandem mass spectrometry analysis. All appeared to be phase I metabolites except for a glucuronide conjugate of a hydroxylated metabolite that was detected at trace levels. A constant neutral loss scan experiment performed on a triple quadrupole mass spectrometer proved to be very useful for resolving the metabolites from endogenous compounds. It was observed that the initial site of metabolism of MK-0767 was at the TZD ring leading to two major metabolites, namely the 5-hydroxy-TZD metabolite (M24) and the mercapto metabolite (M22). The latter was formed via the cleavage of the TZD ring with the elimination of the carbonyl adjacent to the sulfur atom. The structure of M24 was established by accurate mass measurements and NMR analysis. This hydroxy-TZD metabolite might represent an important precursor for a group of metabolites formed by TZD ring opening and subsequent loss of the sulfur moiety. The mercapto metabolite, on the other hand, is probably the key precursor for the TZD ring-opened metabolites with retention of the sulfur, even though the detailed mechanism of the ring scission remains to be characterized. From these studies, it was concluded that the TZD ring was the major site of metabolism of MK-0767. All the metabolites produced in vitro from human preparations were detected in the corresponding preparations from the nonclinical species.
研究了新型含2,4-噻唑烷二酮(TZD)的过氧化物酶体增殖物激活受体α/γ激动剂MK-0767[(±)-5-[(2,4-二氧代噻唑烷-5-基)甲基]-2-甲氧基-N-[[(4-三氟甲基)-苯基]甲基]苯甲酰胺]在大鼠、犬、猴和人肝微粒体及肝细胞以及含重组人CYP3A4的微粒体中的体外代谢情况。通过液相色谱-串联质谱分析检测到22种代谢物(有些为痕量水平)。除了一种痕量水平检测到的羟基化代谢物的葡萄糖醛酸缀合物外,其余似乎均为I相代谢物。在三重四极杆质谱仪上进行的恒定中性丢失扫描实验证明对从内源性化合物中分辨代谢物非常有用。观察到MK-0767的初始代谢位点在TZD环,产生两种主要代谢物,即5-羟基-TZD代谢物(M24)和巯基代谢物(M22)。后者是通过TZD环的裂解并消除与硫原子相邻的羰基形成的。M24的结构通过精确质量测量和核磁共振分析确定。这种羟基-TZD代谢物可能是由TZD环开环并随后失去硫部分形成的一组代谢物的重要前体。另一方面,巯基代谢物可能是保留硫的TZD环开环代谢物的关键前体,尽管环断裂的详细机制仍有待确定。从这些研究得出结论,TZD环是MK-0767的主要代谢位点。在体外人制剂中产生的所有代谢物在相应的非临床物种制剂中均被检测到。